GV joins $50 million round in Rome Therapeutics to research ‘junk DNA’ for cancer therapies

ByJerome Smith
gv-joins-$50-million-round-in-rome-therapeutics-to-research-‘junk-dna’-for-cancer-therapies

http://feedproxy.google.com/~r/venturebeat/SZYF/~3/icgcU0DPK00/

Rome Therapeutics, a biotechnology startup that’s using machine learning (ML) to explore the human genome and develop new treatments for cancer and autoimmune diseases, has launched out of stealth today with $50 million in series A funding from GV, Arch Venture Partners, and Partners Innovation Fund.
Rome was incubated inside GV by CEO and cofounder Rosana Kapeller (M.D.,  » ….